References
- Kramer WM, Rash BF, Jr. Mammary duct proliferation In the elderly: a histopathologic study. Cancer 1973:31:130–7
- Bonte J. Endocrine factors. including antiovulatory steroids, favoring breast disease. In: Castalazo-Ayala L. MacGregor C. eds. Gynecology and obstetrics. Amsterdam: Excerpta Medica. 1977:139
- Haagensen CD, Lane N, Lattea R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978:42:737–69
- Pllnik S. Clinical diagnosis of benign breast diseases. J Reprod Med 1979:22:277–90
- Gautherie M, Groa CM. Breast thermography and cancer risk prediction. Cancer 1970:45:51
- Hobbins W. Thermography—highest risk marker for breast cancer 1980. Proceedings, French Thermographic Society. Lyons. France: 1980. Jun 23
- Gautherie M. Contribution of infrared thermography to early diagnosis, pretherapeutic prognosis and post irradiation follow up of breast carcinomas. Medica Mundi 1976:21(3):135–49
- Isard HJ, Becker W, Shilo R, et al. Breast thermography after four years and 10.000 studies. AJR 1972:115:811–21
- Lets HP, Jr. Epidemiology of breast cancer Identification of the high risk woman. In: Gallagher HS. Leis HP, Jr. Snyderman RK. et al. eds. The breast. St Louis: CV Mosby. 1978
- Hoff J, Portet R, Becue J. et al. La signification de l'écoulement par le mamelon en pathologic mammaire. Gynecologic 1980:31:191
- Ory H. Cole P. MacMahon B, et al. Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 1976:294:419–22
- Novak E. Chronic cystic mastitis (cyclomastopathy). In: Novak E. Gynecology and female endocrinology. Boston: Little Brown. 1941:545
- Gambrell RD. Jr, Massey PM, Castaneda TA, et al. Breast cancer and oral contraceptive therapy in premenopausal women. J Reprod Med 1979:23:265–71
- Chinuki S, Koyama M. The extravascular fluid around the apocrine glands in mastopathy treated with hormones. Yonago Acta Med 1966:10:211–23
- Montgomery AC, Palmer BV, Biswas S, et al. Treatment of severe cyclical mastalgia J R Soc Med 1979:72:489
- Ricciardi I, Ianniruberto A. Tamoxifen-induced regression of benign breast lesions Obstet Gynecol 1979:54:80–4
- Mauvais-Jaxvia P, Kuttenn P, Ohlglesser C. Resultats du traitement de mastodynies et de mastopathies par la progestérone percutanée. Nouv Presse Med 1974:3:1027–8
- Lanersen NH, Wilson KH. The effect of danazol in the treatment of chronic cystic mastitis. Obstet Gynecol 1976:48:93–8
- Humphrey LJ, Estes NC. Aspects of fibrocystic disease of the breast: treatment with danazol. Postgrad Med J 1979:55:48–51
- Baker HW, Snedecor PA. Clinical trial of danazol for benign breast disease. Am Surg 1979:45:727–9
- Andrews WC. The effectiveness of danazol in treating fibrocystic breast disease. Proceedings. Symposium on Fibrocystic Disease of the Breast. Washington DC: 1979. May 4
- Greenblatt RB, Dmowski WP, Mahesh VB, et al. Clinical studies with an antlgonadotropin—danazol. Fertil Steril 197122:102–12
- Nezhat C, Aach RH, Greenblatt RB. Danazol for benign breast disease. Am J Obstet Gynecol 1980:137:604–7
- Greenblatt RB, Dmowskl WP, Mahesh VB, et al. Clinical studies with an antlgonadotropin—danazol. Fertil Steril 1971:22:102–12
- Barbieri RL, Canic JA, Makris A, et al. Danazol inhibits steroidogenesis. Fertil Steril 1977:28:809
- Minton JP, Foecking MK, Webster DJ. et al. Response of fibrocystic disease to caffeine withdrawal and correlation of cyclic nucleotides with breast disease. Am J Obstet Gynecol 1979:135:157–8
- London RS, Solomon DM, London ED, et al. Mammary dysplasia: clinical response and urinary excretion of 11-deoxy-17 ketosteroids and pregnanediol following alphatocopherol therapy. Breast 1978:4:19